• +1-646-491-9876
    • +91-20-67278686

    Search

    Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017

    Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017

    • Report Code ID: RW0001767486
    • Category Pharmaceuticals
    • No. of Pages 397
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

    Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 23, 11, 35, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.

    Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Graft Versus Host Disease (GVHD) - Overview 6
    Graft Versus Host Disease (GVHD) - Therapeutics Development 7
    Graft Versus Host Disease (GVHD) - Therapeutics Assessment 22
    Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 34
    Graft Versus Host Disease (GVHD) - Drug Profiles 65
    Graft Versus Host Disease (GVHD) - Dormant Projects 369
    Graft Versus Host Disease (GVHD) - Discontinued Products 373
    Graft Versus Host Disease (GVHD) - Product Development Milestones 374
    Appendix 385

    List of Tables

    Number of Products under Development for Graft Versus Host Disease (GVHD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Nektar Therapeutics, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH, H1 2017
    Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
    Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017
    Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Graft Versus Host Disease (GVHD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    AbGenomics International Inc
    Allergan Plc
    Amunix Operating Inc
    AnaptysBio Inc
    apceth Biopharma GmbH
    Aptevo Therapeutics Inc
    arGEN-X BV
    Athersys Inc
    Bellicum Pharmaceuticals Inc
    Bio-Cancer Treatment International Ltd
    Biogen Inc
    Bristol-Myers Squibb Company
    Capricor Therapeutics Inc
    Cell2B Advanced Therapeutics SA
    CellECT Bio Inc
    Commence Bio Inc
    Cynata Therapeutics Ltd
    Cytodyn Inc
    Dr. Falk Pharma GmbH
    Escape Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Fate Therapeutics Inc
    Generon (Shanghai) Corp Ltd
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Incyte Corp
    Jazz Pharmaceuticals Plc
    Kadmon Corp LLC
    Kamada Ltd
    Kiadis Pharma NV
    Kymab Ltd
    Kyorin Pharmaceutical Co Ltd
    MacroGenics Inc
    Mallinckrodt Plc
    Mesoblast Ltd
    Millennium Pharmaceuticals Inc
    Nektar Therapeutics
    Nohla Therapeutics Inc
    Novartis AG
    OncoImmune Inc
    OSE Immunotherapeutics
    Pfizer Inc
    Pharmicell Co Ltd
    REGiMMUNE Corp
    Sanofi
    Sarepta Therapeutics Inc
    Seattle Genetics Inc
    Seres Therapeutics Inc
    Sigmoid Pharma Ltd
    Synedgen Inc
    Takeda Pharmaceutical Company Ltd
    Targazyme Inc
    TC BioPharm Ltd
    TxCell SA
    United BioPharma Inc
    Vault Pharma Inc
    VBI Vaccines Inc
    Xenikos BV
    XL-protein GmbH
    ZIOPHARM Oncology Inc

    Request for Sample

    Report Url http://www.reportsweb.com//graft-versus-host-disease-gvhd-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//graft-versus-host-disease-gvhd-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//graft-versus-host-disease-gvhd-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments